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SUMMARY 
Since decades, hematopoietic stem cell transplantation (HSCT) has become a well 
established treatment modality for hematological malignancies and non-malignant 
disorders. Autologous and allogeneic hematopoietic stem cells (HSCs) mobilized into 
the peripheral blood (PB) have been used as a preferred source of transplantable stem 
cells1-3. And umbilical cord blood (UCB) has been introduced as a more attractive 
HSC source for HSCT, because fetal stem cells in UCB are speculated to be more 
primitive in comparison to adult stem cells. However the limited amount of HSCs is 
limiting their application for stem cell therapy in clinic. Therefore, people started to 
utilize extra-embryonic tissue to harvest more fetal stem cells, while people also tried 
to optimize the clinical protocol to mobilize more adult stem cells out of adult bone 
marrow. The innovative strategies and feasible procedures were discussed in this 
thesis. 
 
The axis of the chemokine receptor CXCR4 and its ligand SDF-1 is important for 
trafficking and homing of HSCs. It has already been demonstrated that the bicyclam 
AMD3100, a CXCR4 antagonist, in combination with G-CSF is able to induce a 
significant mobilization of CD34+ cells4. And human placenta is a potent 
hematopoietic niche containing hematopoietic stem and progenitor cells throughout 
development5. The homing of HSCs to the placenta is probably also mediated by the 
expression of SDF-1 as demonstrated for the bone marrow niche. In this study (part 1 
of the chapter “Results and discussions”), we utilized AMD3100 to mobilize HSCs 
from placenta. And we can demonstrate that the CXCR4 antagonist AMD3100 
mobilise placenta derived CD34+ cells ex utero already after 30 min of incubation 
and may further enhance the efficacy of harvesting placenta-derived HSC. 
 
The alpha4 integrin CD49d is involved in migration and homing of hematopoietic 
stem cells (HSC). Therapeutic application of natalizumab, an anti-CD49d antibody, in 
patients with multiple sclerosis (MS) has been associated with increased levels of 
circulating CD34+ progenitors. In our study (part 2 of the chapter “Results and 
discussions”), we compared circulating HSCs from MS patients after natalizumab 
treatment and HSCs mobilized by G-CSF in healthy volunteers, with regard to their 
migratory potential, clonogenicity and gene expression. CD34+ cells in the blood and 
marrow of natalizumab-treated patients expressed less of the stem cell marker CD133, 
were enriched for erythroid progenitors (CFU-E) and expressed lower levels of 
adhesion molecules. The level of surface CXCR-4 expression on CD34+ cells from 
patients treated with natalizumab was higher compared to that of CD34+ cells 
mobilized by granulocyte-colony stimulating factor (G-CSF) (median 43.9% vs. 
15.1%). This was associated with a more than doubled migration capacity towards a 
chemokine stimulus. Furthermore, CD34+ cells mobilized by natalizumab contained 
more m-RNA for p21 and less MMP9 compared to G-CSF mobilised HSC. Our data 
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indicate that G-CSF and CD49d blockade mobilize different HSC subsets and suggest 
that both strategies may be differentially applied in specific cell therapy approaches. 
 
In order to further improve the clinical outcome of HSC transplantation, many groups 
are focusing on ex vivo maintain or expand HSC. Unfortunately, the maintenance of 
HSC in vitro is difficult to achieve because of their differentiation. This is presumably 
caused by a lack of appropriate cues that are provided in vivo by the 
microenvironment. Indeed, HSCs located in the bone marrow are interacting with a 
specific microenvironment referred to as the stem cell niche, which regulates their fate 
in terms of quiescence, self-renewal and differentiation. An orchestra of signals 
mediated by soluble factors and/or cell-to-cell contact keeps the balance and 
homeostasis of self-renewal, proliferation and differentiation in vivo. To investigate 
the communication between HSCs and the niche, coculture assays with mesenchymal 
stromal cells (MSCs) were performed in vitro. Here, we can demonstrate that 
cell-to-cell contact has a significant impact on hematopoietic stem cells expansion, 
migratory potential and stemness. In this study (part 3 of the chapter “Results and 
discussions”), we investigated in more detail the spatial relationship between 
hematopoietic stem cells and mesenchymal stromal cells during ex-vivo expansion. 
And we defined three distinct localizations of HSCs relative to MSC layer: (i) those in 
supernatant (non-adherent cells); (ii) cells adhering on the surface of mesenchymal 
stromal cells (phase-bright cells) and (iii) cells beneath the mesenchymal stromal cells 
(phase-dim cells). Our data suggest that the mesenchymal stromal cell surface is the 
dominant location where hematopoietic stem cells proliferate, whereas the 
compartment beneath the mesenchymal stromal cell layer seems to be mimicking the 
stem cell niche for more immature cells. Our data provide novel insight into the 
construction and function of three-dimensional HSC–MSC microenvironments. 
 
In summary, we provided a new method to isolate fetal stem cells from 
extra-embryonic tissue (i.e. placenta) in the first part, then we discussed an innovative 
strategy with CD49d blockade to improve clinical modality for adult stem cell 
mobilization in the second part, and finally we investigated HSC maintenance and 
expansion in vitro and provided feasible way to mimic HSC niche in vitro in the last 
part.  
 
This thesis contributes to HSC-based stem cell therapy in two aspects, i.e. 1) fetal and 
adult stem cell isolation holding great therapeutic potential for blood diseases; 2) ex 
vivo stem cell manipulation providing a valuable platform to model HSC niche 
regulation.  
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INTRODUCTION 
1. Isolation of primary human Hematopoietic Stem Cells 
Hematopoietic stem cells (HSCs) are defined by their ability to give rise to all types of 
blood cells 6-8. During the last three decades hematopoietic stem cell transplantation 
(HSCT) has become a well established treatment for hematological malignancies and 
non-malignant disorders. Lately HSCs are attracting more and more attention for their 
potential use in regenerative medicine and tissue engineering 9. In clinic, human 
primary HSCs can be harvested from healthy donors either by bone marrow aspiration, 
peripheral stem cell mobilization or from cord blood. In this study, we firstly 
investigated two alternative ways for HSC mobilisation. 
 
1.1 HSC mobilization out of Placenta after Cord Blood collection 
Allogeneic bone marrow and peripheral blood stem cell transplantation is the 
treatment of choice for some malignant hematologic diseases, marrow failure 
syndromes, and severe congenital immunodeficiency states. Since Gluckman et al 
reported in 1988 the first successful transplantation of human umbilical cord blood 
(UCB), UCB has been used increasingly in both pediatric and adult patients. However 
the limiting factor of UCB transplantation is the low amount of hematopoietic stem 
cells (HSC) 10. Therefore many groups are working on an optimized collection 
procedure. A Spanish group could demonstrate that a modified in utero / ex utero 
two-step collection method in which a cord blood fraction obtained by umbilical venal 
puncture was combined with a second fraction harvested after placental perfusion 
with 50 ml heparinised 0.9% saline could significantly increase the amount of 
nucleated cells 11.  
 
The axis of the chemokine receptor CXCR4 and its ligand SDF-1 is important for 
trafficking and homing of HSC. AMD3100 is able to mobilize CD34+ HSC in mouse 
and men. Especially in so called poor mobilizer AMD3100 in combination with 
G-CSF is able to induce a sufficient mobilisation of CD34+ cells12. Dipersio et al have 
already shown that AMD3100 may provide an alternative method of HSC 
mobilisation of allogeneic donors13. We were interested to investigate if AMD3100, a 
CXCR4 antagonist, is able to mobilize HSC from the placenta.  
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1.2 HSC mobilization out of Bone Marrow  
Autologous and allogeneic hematopoietic stem cells (HSC) mobilized into the 
peripheral blood (PB) have been used as a preferred source of transplantable stem 
cells1-3. In order to facilitate a rapid and efficient mobilization of HSC, donors or 
patients are treated with granulocyte colony stimulating factor (G-CSF) which causes 
a transient release of HSC out of the bone marrow (BM)14-16. However, the number of 
HSC mobilized by G-CSF shows a broad interindividual variation17. Since as many as 
14% of autologous donors demonstrate a poor response to G-CSF18, more efficient 
strategies for HSC mobilization have to be developed. One strategy which has already 
been introduced in clinical trials is the combination of G-CSF with the CXCR-4 
antagonist Plerixafor allowing a significantly better mobilization especially in heavily 
pretreated patients with NHL or Multiple Myeloma19.  
 
Moreover, antibodies against the Very-late antigen 4 (VLA-4) have shown some 
promise to mobilize long-term repopulating hematopoietic progenitors in preclinical 
models20,21. Natalizumab, a human monoclonal antibody against integrin α4 (CD49d), 
is used in the clinic to treat Multiple Sclerosis (MS). Recently, it has been reported 
that a marked increase in the number of circulating HSC can be observed during 
natalizumab treatment in MS patients22,23. These reports have raised great interest 
since they have opened the perspective to explore CD49d blockade as a new 
mobilization strategy. Nevertheless the phenotypes and functions of HSC mobilized 
with natalizumab and the impact on steady-state hematopoiesis in the bone marrow 
have not been characterized in detail. Therefore, in our study, BM, PB, and purified 
CD34+ cells of MS patients after Natalizumab treatment were evaluated in 
comparison to BM and G-CSF mobilized PB from healthy donors as well as to PB of 
MS patient without natalizumab treatment. Our data for the first time show that 
chronic administration of Natalizumab leads to an increase in BM CD34+ cells and 
that CD34+ cells mobilized into the peripheral blood have a different phenotype and 
migratory potential compared to G-CSF mobilized CD34+ HSC. 
 
 
2. Hematopoietic Stem Cells in Coculture with Mesenchymal 
Stromal Cells 
To improve the clinical outcome of autologous and allogeneic HSC transplantation 
many groups are focusing on ex vivo expansion of HSCs particularly in cases with a 
limited graft size. Unfortunately, the expansion of HSC in vitro is difficult to achieve 
because their proliferation is accompanied by differentiation 24. This is presumably 
caused by a lack of appropriate cues that are provided in vivo by the 
microenvironment. Indeed, HSCs are located mainly in the bone marrow where they 
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interact within a specific microenvironment called the stem cell niche, which 
regulates their fate in terms of quiescence, self-renewal and differentiation 25-27. 
Recent data suggest that quiescent HSCs are primarily located in the trabecular 
endosteum (i.e. osteoblastic niche) whereas dividing ones reside in sinusoidal 
perivascular areas (i.e. vascular niche) of the bone marrow 28,29. In response to stress 
or injury, HSCs can be released from the vascular niche into the circulation 30. An 
orchestra of signals mediated by soluble factors and/or cell-to-cell contact keeps the 
balance and homeostasis of self-renewal, proliferation and differentiation in vivo 31. 
Though important regulatory components of the stem cell niche in vivo have been 
identified, this has not been translated into improved ex vivo expansion protocols for 
clinical applications. The most excellent defined culture medium for HSC expansion 
is supplemented with cytokines such as fetal liver tyrosine kinase-3 ligand (FLT3-L), 
stem cell factor (SCF), interleukin-3 (IL-3) and thrombopoietin (TPO) 32,33. 
Interestingly, mesenchymal stromal cells (MSCs), which are characterized by 
multi-differentiation potential 34,35, are important players of the bone marrow HSC 
niche 36. In recent years, MSCs have been shown to support HSC maintenance and 
engraftment 37,38. In addition, an immuno-modulatory capacity of MSCs has been 
described 39.  
 
According to several recent studies including those from our laboratory, MSCs 
facilitate HSC maintenance in a coculture system in vitro via the secretion of soluble 
factors and cell-cell contact 40-43. In addition evidence is emerging that a 
three-dimensional architecture is important to mimic physiologic conditions ex vivo 
30,44. Therefore we were prompted to investigate how HSCs interact with MSCs in 
different spatial compartments over time in vitro. Usually HSCs in the coculture were 
considered as a single population, and their localization relative to the MSC layer has 
not been investigated intensively. In this study, MSCs served as a physical boundary 
of distinct compartments, and the properties and features of HSCs in different 
localizations were evaluated at various times. Our data provides novel insight into the 
construction and function of a three-dimensional HSC–MSC coculture 
microenvironment in vitro. 
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DESIGN AND METHODS 
1. Stem Cell Isolation and manipulation 
Samples 
Peripheral blood (PB) and bone marrow (BM) of healthy volunteers and some patients 
were investigated in this study. Briefly, mobilized PB was collected from healthy 
donors after treatment with 7.5 µg/kg granulocyte colony-stimulating factor (G-CSF) 
for 5 days. And PB was also collected from MS patients who had not responded to 
other immunomodulatory treatment, received 300 mg natalizumab IV at monthly 
intervals (Tysabri, Biogen Idec, Cambridge, MA, USA). BM was aspirated from 
healthy donors and the patients. Written informed consent was obtained in all cases.  
 
Purification of CD34+ cells  
CD34+ HSC were purified from leukapheresis samples by attachment to magnetic 
beads conjugated with CD34 antibody, according to the manufacturer’s instructions 
(MACS, Miltenyi Biotec). The purities for the HSC fraction derived from samples 
mobilized by G-CSF were 95.6±0.9% and for natalizumab 91.2±0.6%as assessed by 
flow cytometry analysis using PE conjugated CD34 antibody (Miltenyi Biotec, 
Germany). Trypan blue exclusion confirmed >96% vitality in every sample. 
 
Isolation of mesenchymal stromal cells 
MSCs were isolated from bone marrow aspirates after informed consent and approval 
by the local ethics committee and cultured as described previously45. The phenotype 
of all MSC batches was tested by fluorescence-activated cell sorting (FACS): The 
presence of CDw90, CD105, CD166, and CD73, and absence of CD34 and CD45 
were required. MSC batches used in the cocultures had been tested for their potential 
to differentiate along the osteogenic and adipogenic lineages using standard 
commercial differentiation media. MSCs of passage two were then seeded in 12-well 
plates or 24-well plates at a density of 1 x 104/cm2 with MSC medium. The medium 
was changed every 3 days until the MSC feeder layer reached confluence.  
 
Mobilize HSCs from Placenta 
The first blood fraction was obtained from the placenta ex utero after delivery of the 
placenta. After the blood flow ceased the placental vessels were flushed with 30 ml 
0.9% saline supplemented with 10µg/ml AMD3100. Then 30 min of incubation and 
collected the fraction were performed. HSCs were identified. 
 
Coculture of hematopoietic stem cells with mesenchymal stromal cells layer  
CD34+ HSCs were suspended in CellGro® SCGM medium (CellGenix, Freiburg, 
Germany) with 10% FCS, 150 ng/ml Fetal Liver Tyrosine Kinase-3 ligand (FLT3-L), 
150 ng/ml stem cell factor (SCF) (both Biosource, Camarillo, CA, USA) and 50 ng/ml 
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IL-3 (Miltenyi Biotec, Germany). HSC suspensions were plated at a density of 1 x 104 
cells/cm2 on confluent MSC layer at 37°C in normaxia or hypoxia condition (lower 
than 1% O2 tension).  
In some experiments HSCs were cultured without MSCs in a cytokine-driven assay. 
After 4 days the cell suspension containing around 50% CD34+CD38- cells was 
seeded on an MSC layer for 5 hours for further analysis. 
 
2. Analyses on stem cells before and after manipulation in vitro 
Flow cytometric immunophenotyping  
Immunophenotyping was by four-color lyse-wash flow cytometry. Progenitor cells 
were identified using CD34-APC and CD45-PerCP5.5 (BD Biosciences, Heidelberg, 
Germany). Two further antibodies, labeled with FITC or PE, were added for 
characterizing expression of the following adhesion molecules:  CD11a/CD18, 
which is a beta2 integrin, also called lymphocyte function-associated antigen-1 (LFA 
1; BD Biosciences), CD62L L-selectin, and CD31, the platelet endothelial cell 
adhesion molecule PECAM (both from Beckman-Coulter, Krefeld, Germany), plus 
heparan sulphate proteoglycan CD44 and integrin a4 (CD49d) (Biozol, Esching, 
Germany). The chemokine receptor CXCR-4/CD184 (BD Biosciences) and the stem 
cell antigen CD133 (Miltenyi Biotec, Bergisch Gladbach, Germany) were also 
evaluated. Stem cells were selected by gating as CD34+CD45dim cells with low side 
scatter. Whenever possible, 2000 stem cells with about 500,000 events overall were 
registered. Fluorescence-minus-one controls for FITC and PE provided the threshold 
setting for adhesion molecule expression. All measurements were performed on a 
FACS Canto II flow cytometer equipped with three lasers (488nm, 633nm, and 
405nm) using FACS DiVa software. Percentages and mean fluorescence intensity 
(MFI) were assessed. Appropriate murine antibodies served as a negative isotype. 
 
Proliferation assay 
Purified CD34+ cells were suspended in CellGro® SCGM medium (CellGenix, 
Freiburg, Germany) with 10% FCS, 150 ng/ml fetal liver tyrosine kinase-3 ligand 
(FLT3-L), 150 ng/ml stem cell factor (SCF) (both from Biosource, Camarillo, CA, 
USA), and 50 ng/ml interleukin-3 (IL-3) (Miltenyi Biotec). HSC suspensions were 
plated at 4 x 104 cells/well in 6-well plates at 37°C and 5% CO2. The number of total 
nucleated cells (TNC) was counted on days 1, 3, 5 and 7 by Trypan Blue (vitality 
more than 95%). 
 
CFU-GM assay in unmanipulated leukapheresis samples 
1 x 105 cells from each leukapheresis sample were plated in 35-mm Petri dishes 
(Greiner, Frickenhausen, Germany) in a total volume of 1ml standard methylcellulose 
medium with recombinant cytokines (MethoCult GF+ H4435; Stem Cell 
Technologies, Vancouver, Canada) in triplicate. All cultures were incubated at 37°C in 
fully humidified air with 5% CO2. After 14 days, erythroid bursts (BFU-E), myeloid 
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colonies (CFU-GM), and mixed-cell colonies (CFU-GEMM) were scored with an 
inverted light microscope (Carl Zeiss, Jena, Germany). Colonies were defined as 
clusters consisting of ≥40 cells. The frequency of colonies is provided per 1000 
CD34+ cells inserted.  
 
Immunofluorescence microscopy 
After coculture the supernatant was discarded and the MSC layer was washed twice 
gently. Next the remaining cells including phase-bright and phase-dim cells along 
with the MSC layer were fixed using 3.8% formaldehyde in PBS for 15min and 
permeabilized using 0.1% Triton X-100 in PBS for 3-4min. After blocking, cells were 
incubated with CD45-PE (1:10; Miltenyi Biotec, Germany) for 1h and then incubated 
with anti-mouse-TRITC (1:400; Sigma, USA) and phaloidin-ALEXA488 (1:500; 
Invitrogen, UK) for 1h in RT. Then nuclei were labelled with DAPI (Sigma, USA). 
Finally fluorescence imaging was performed by confocal microscopy (Zeiss LSM 510, 
Germany).  
 
Scanning electron microscopy 
Samples for the scanning electron microscopy analysis were prepared as previously 
described 46. Briefly, the co-cultured cells growing on fibronectin-coated coverslips 
were fixed in 2% glutaraldehyde for 1 h at RT and then overnight at 4°C. After being 
subjected to dehydration in an acetone gradient (30-100%), cells were critical 
point-dried in a CO2 system (Critical Point Dryer CPD 030, BAL-TEC GmbH, 
Germany). Samples were then sputter-coated with gold (Sputter Coating Device SCD 
050, BAL-TEC GmbH) and examined at 10 kV accelerating voltage in an 
environmental scanning electron microscope (PHILIPS XL 30 ESEM FEG, Philips, 
The Netherlands). 
 
Time-lapse video microscopy 
Freshly isolated CD34+ HSCs were cultured on MSCs growing on 24 x 60 mm 
fibronectin-coated coverslips – attached to a silicone reusable chamber. During the 
time-lapse recording, cells were kept in a 37°C chamber with a 5% CO2 atmosphere. 
Serial phase contrast images were captured with an inverted microscope (Zeiss 
Axiovert 200M; 20X objective) at 30 sec intervals. The images were built into a 
movie using the Metamorph software.  
 
Cell collection from three distinct localizations 
HSCs from 3 distinct compartments in coculture were collected separately as 
described HSC/MSC cocultures were prepared as described above. On each day 
during the first week HSCs from 3 distinct localizations in coculture were collected 
separately. Briefly, the supernatant of the coculture was aspirated and the cells in the 
supernatant (non-adherent cells) were collected. The MSC layer was gently washed 
twice with PBS to remove the remaining non-adherent cells. After washing, the cells 
remaining on the MSC layer (phase-bright cells) were collected by further intensive 
washing steps with PBS. When no phase-bright cells could be observed under 
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phase-contrast microscopy, the MSC layer with the cells underneath the layer 
(phase-dim cells) was trypsinized and collected as well. To exclude a trypsin effect, 
non-adherent cells and phase-bright cells were also trypsinized for 5 min. No notable 
change in the mean intensity of CD38 was observed after trypsinization, showing 
CD38 antigen is relatively resistant to digestion by trypsin47. Finally the three cell 
fractions were counted by Trypan Blue (vitality more than 95%) and measured as 
described below.  
 
Cell cycle analysis using Propidium Iodide (PI) 
After cell collections each time, cells were fixed at 4°C overnight with cold 70% 
ethanol. Then the cells were washed and incubated in PBS with 50µg/ml PI and 
1mg/ml RNase for 30 min in RT. After washing, the cells were measured by flow 
cytometry (FACScalibur; BD, Germany). Finally, the FACS data were analyzed using 
Modifit software (Becton Dickinson), and the proportions of G0/G1 phase, S phase 
and G2/M phase of cell cycle were calculated automatically. 
 
PCR analysis 
After 5 days coculture, cells from the three compartments were labeled with 
antihuman CD45-FITC and CD166-PE. Then, cells were sorted and MSCs were 
discarded based on forward-scatter (FSC), side-scatter (SSC), and CD45+CD166- 
staining using BD FACSAria and software B&D FACSDiva. Total RNAs isolated by 
Trizol reagent (Invitrogen, USA) were reverse transcripted to total cDNAs with oligo 
dT. And a quantitative TaqMan real-time polymerase chain reaction (RT-PCR) was 
performed for Cyclin-dependent kinase inhibitor 1A (CDKN1A, p21) according to the 
Taqman manufacturer’s instructions (Applied Biosystems, USA). The housekeeping 
gene GAPDH was used as a control. All primers were purchased from Applied 
Biosystems (USA). The relative gene expression of p21 was calculated by 
normalization to the expression level in phase-bright cells which was considered as 1. 
 
Cell generation tracking with CFSE staining 
Generations of HSCs were identified using CellTraceTM CFSE Cell Proliferation Kit 
(Invitrogen, UK). Briefly, CD34+ HSCs were labelled by CFSE according to the 
manufacturer’s instructions and placed in coculture with MSCs as described above. At 
fixed time points, the cells from the respective compartment were collected and 
analyzed using FACS. The number of cell divisions was quantified according to CFSE 
signal intensity using CellQuest software. As control CD34+ HSCs were labelled with 
CFSE and treated with 50µg/ml Mitomycin (Santa Cruz) to arrest the cell population 
at generation 0. 
The CD34 expression pattern throughout subsequent cell generations was evaluated 
by CD34-APC and CFSE double staining.  
 
Transwell migration assay 
A 600µl aliquot of conditional medium or serum-free medium containing 300 ng/ml 
stromal cell-derived factor-1 (SDF-1; R&D Systems, Minneapolis, MN, USA) was 
 14
added to the lower chamber of a 5-µm 24-well polycarbonate transwell culture dish 
(Corning Costar Corporation, Cambridge, MA, USA). Subsequently, 2 x 105 fresh 
HSCs or expanded HSCs were suspended in 0.1 ml medium and added to the upper 
chamber to migrate for 4 hours at 37°C. Cells that had migrated into the lower 
chamber were collected and counted. Spontaneous migration towards serum-free 
medium without SDF-1 addition was estimated as a control. 
 
Inhibition of hematopoietic stem cell migration under mesenchymal stromal 
cells by blocking Integrin ß1 and CXCR4 
HSCs were cultured in suspension without a MSC layer for 2 days. These primed 
HSCs started to migrate under the MSC layer within 5 hours. In addition, the primed 
HSCs were preincubated for 1h in normal culture medium (CM) supplemented with 
10µg/ml P-selectin antibody (BD, Germany), or with 10µg/ml Integrin ß1 antibody 
(BD, Germany) 48, or with 500ng/ml AMD3100 (a nonpeptide antagonist of CXCR4; 
Sigma, USA) 43, or with both 500ng/ml AMD3100 and 10µg/ml Integrin ß1 antibody. 
After blocking, 1x105/ml cells were plated on the MSC layer for 5 hours. Finally 
HSCs from distinct localizations were counted using trypan blue as mentioned before. 
 
Statistics of cell division to time and cell passage differentiation  
All data were derived from at least three independent experiments. Data were 
represented as “mean ± standard error of the mean (SEM)” and analyzed with the 
paired student’s test. Observed differences were regarded as significant if the 
calculated two-sided p-value was below 0.05.  
 
 
 
 15
RESULTS AND DISCUSSIONS 
Part 1: AMD3100 Mobilization of Human Hematopoietic Progenitor 
Cells from the Placenta (Bone Marrow Transplantation, 2010 Feb 22.) 
 
Duohui Jing, Nael Alakel, Martin Bornhäuser, Gerhard Ehninger and Rainer Ordemann 
Medical Clinic and Policlinic I, University Hospital, Dresden, Germany 
 
 
Umbilical cord blood (UCB) has been introduced as an alternative graft source for 
allogeneic hematopoietic stem cell transplantation (HSCT) in both pediatric and 
adult patients. However the limited amount of HSC leads to delayed engraftment 
especially in adult recipients10. Therefore, several groups are working on an 
optimized collection procedure in order to increase the amount of transplantable 
progenitors. Bornstein and colleagues have demonstrated recently that a modified in 
utero / ex utero two-step collection procedure can lead to a significant increase of the 
amount of harvested progenitor cells11.  
 
Especially in patients with a limited hematopoietic capacity the bicyclam AMD3100, 
a CXCR4 antagonist, in combination with G-CSF is able to induce a significant 
mobilisation of CD34+ cells49. Dipersio et al have already shown that AMD3100 
may provide an alternative method of HSC mobilisation even in allogeneic donors13. 
Gene expression data indicate that AMD3100 mobilized HSCs may represent a 
functionally different subset of HSCs50. 
 
As demonstrated for the bone marrow niche, the homing of HSC to the placenta is 
probably also mediated by the expression of SDF-151. Recently Serikov et al. could 
demonstrate AMD3100 is able to mobilize additional HSC from the placenta by 
perfusion of the placenta for up to six hours52. Within a pilot-study we could confirm 
Serikovs data indicating that AMD3100 is able to mobilize hematopoetic progenitor 
cells from the placenta.  
 
First we obtained cord blood samples using standard techniques ex utero after 
delivery of the placenta. After the blood flow had ceased we flushed the placental 
vessels with 30 ml 0.9% saline and 10% ACD to collect the remaining cord blood 
(saline wash). The proportions of CD34+ and CD133+ cells in “saline wash” 
(CD34+%: 0.13% ± 0.03%; CD133+%: 0.05% ± 0.02%) were not significantly 
different to the primary cord blood samples. Then we flushed the placental vessels 
again with 30 ml 0.9% saline supplemented with 10 µg/ml AMD3100. After 30 min 
of incubation the instilled solution was eluted. No clotting was detected. Despite the 
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lower cell concentration in the recollected elution, fluorescence-activated cell sorting 
(FACS) revealed a significant increase (P = 0.01) of the proportion of CD34+ and 
CD133+ cells comparing to cord blood samples in 9 consecutive placenta studies, as 
shown in the Table. The total number of CD34+ cells recovered in 28 ml of rinsing 
solution containing AMD3100 was 0.13 ± 0.034x106. Whether this amount of 
transplantable HSC is clinically meaningful, remains to be studied. As control the 
placenta was incubated with 0.9% saline without AMD3100 for 30 min. No increase 
of the CD34+ or CD133+ cell count was detectable (Table). 
 
In summary our preliminary data demonstrate that the CXCR4 antagonist AMD3100 
mobilise placenta derived CD34+ cells ex utero already after 30 min of incubation 
and may further enhance the efficacy of harvesting placenta-derived HSC. 
 
 
 
 
Table: Comparison of the primary cord blood collection, AMD-Mobilized Cells and 
control (Incubation with saline without AMD3100 for 30 min). 
 Cord Blood AMD Mobilization Control  
Volume (ml) 50 ± 8.4 28 ± 2.0 30 ± 2.0 
Cell Count (x108) 6.20 ± 1.12 0.45 ± 0.12 0.34 ± 0.05 
CD34+% 0.14% ± 0.03% 0.28% ± 0.07% 0.10% ± 0.01% 
CD133+% 0.09% ± 0.02% 0.17% ± 0.04% 0.08% ± 0.01% 
N  
(Placenta number) 9 9 4 
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Part 2: CD49d blockade by natalizumab in patients with multiple 
sclerosis affects steady state hematopoiesis and mobilizes 
progenitors with a distinct phenotype and function (Bone Marrow 
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Duohui Jing1, Uta Oelschlaegel1, Rainer Ordemann1, Gerhard Ehninger1, Heinz Reichmann2, 
Tjalf Ziemssen2, Martin Bornhäuser1,3. 
1Department of Hematology and Oncology, University Hospital Dresden  
2Department of Neurology , University Hospital Dresden 
3Centre for Regenerative Therapies, Dresden, Germany 
 
 
RESULTS 
Frequency of CD34+ progenitor cells. The CD34+ cell concentration was 
significantly higher in the BM of MS patients receiving natalizumab compared to 
values measured in healthy volunteers donating bone marrow donors during the 
same period of time (BM-donor; p=0.005). Interestingly, the frequency of CD34+ 
cells in the BM was directly correlated with the number of natalizumab infusions 
with 617/µl after 15 infusions, 1342/µl after 21 infusions, 1350/µl after 23 infusions 
and 2250/µl after 32 cycles, respectively. As previously shown, an elevated CD34+ 
count was also detectable in PB from MS patients after repetitive natalizumab 
therapy (PB-nat) v.s. PB from MS patients without natalizumab, whereas the CD34+ 
counts of the latter group were comparable to those of steady-state PB in 
unstimulated healthy donors (Figure 2-1).  
 
Repeated measurements, done before and up to 4 days after the first administration 
of natalizumab in two patients, revealed the maximum CD34+ absolute counts on 
day 4 (4/µl and 8/µl, respectively). Almost all adhesion molecules were 
down-regulated after the first natalizumab administration. The blocking of VLA-4 
via natalizumab was reflected as a decrease in mean VLA-4 mean fluorescence 
intensity (MFI) from 4837 before treatment to 3089 after 72h.  
 
Differences in adhesion molecule and CD133 expression. The expression 
(percentage and/or MFI) of most of the tested antigens (L-selectin, Pecam, CD44, 
LFA-1) was lower in both BM and PB of MS patients treated with natalizumab 
compared to healthy donors (Figure 2-2 a-c). Remarkably, CD133 expression on 
CD34+ cells was also clearly lower in the BM as well as in PB of natalizumab 
treated patients compared to healthy donors (BM-donor and PB-donor) (Figure 2-2 
a-c). 
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Figure 2-1: CD34+ cell counts in peripheral blood a) and bone marrow b) Box and whisker plots 
for the CD34+ counts (median and range) in MS patients with or without natalizumab and in 
healthy controls. The boxes represent the lower and upper quartiles, whiskers depict maximum 
and minimum. a) PB-donor, peripheral blood of healthy donors after G-CSF treatment; PB-nat, 
peripheral blood of MS patients after natalizumab therapy; PB-MS, peripheral blood of MS 
patients without natalizumab therapy. b) BM-donor, bone marrow of healthy donors; BM-nat, 
bone marrow of MS patients receiving natalizumab. Tables provide median and ranges and 
number of patients studied. 
 
 
 
 
 
 
 
 19
 
 
 
 
 
 
Figure 2-2: Phenotype of CD34+ cells in natalizumab treated patients and controls Graphs a) and 
b) summarize the percentage of cells being positive for the respective markers as measured by 
fluorescence activated cell sorting (FACS). Black and grey dots represent values from G-CSF 
mobilized healthy donors and MS patients, respectively. In graph c) the mean fluorescence 
intensity (MFI) is provided to quantify the expression of adhesion molecules on peripheral blood 
cells. PB-donor, peripheral blood of healthy donors after G-CSF treatment; PB-nat, peripheral 
blood of MS patients after natalizumab therapy; BM-donor, bone marrow of healthy donors; 
BM-nat, bone marrow of MS patients receiving natalizumab. *p< 0.05; ** p< 0.01. 
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Stem cell subpopulations in purified CD34+ cells.  Besides BM and mobilized PB 
from MS patients after natalizumab, purified CD34+ cells from apheresis samples 
(HSC-nat) also expressed the primitive hematopoietic antigen CD133 less than the 
G-CSF mobilized control cells (G-CSF HSC) did. However, no significant 
differences were observed in the CD34+CD38- compartment (data not shown). The 
expression of CXCR-4 (CD184) on CD34+ cells from natalizumab-treated patients 
was significantly higher than on G-CSF mobilized CD34+ cells from healthy 
controls (43.9% (range, 42.3–52.9%) vs 15.1% (range, 7.8–17.8%), p < 0.05, Figure 
2 - 3 b ) .  R e p r e s e n t a t i v e  c o n t o u r  p l o t s  a r e  s h o w n  i n  F i g u r e  2 - 3 a . 
 
Transwell migration assay. The increased expression of CXCR-4, as described above, 
was associated with a significantly better migration of CD34+ cells from patients 
receiving natalizumab compared to G-CSF mobilized CD34+ cells measured 4 h 
after establishing a chemotactic stimulus (SDF-1) (13.4% (range, 12.2–17.1%) vs 
6.1% (range, 4.9–7.4%), p < 0.05, Figure 2-3c). 
 
Gene expression and cell cycle analysis. In our study, MMP9 mRNA was 
significantly diminished in natalizumab mobilized CD34+ cells whereas p21, a 
negative regulator of cell cycle, was significantly upregulated in CD34+ cells 
mobilized by natalizumab (2.15 fold (range, 1.62-2.74 folds)). Correspondingly, the 
mRNA level of G0S2, a gene involved in cell cycle progression was decreased 
(Figure 2-4). 
 
Ex-vivo expansion and clonogenicity. The proliferation capacity of CD34+ selected 
cells derived from leukapheresis products after 7 days of in vitro culture is shown in 
Figure 2-5a. The absolute cell numbers were not significantly different after 7 days 
of culture in vitro. Consistent with the lower frequency of CD34+ cells in the 
peripheral blood of natalizumab treated patients (Figure 2-1), the absolute number of 
BFU-E and CFU-GM contained in leukapheresis samples was lower than in G-CSF 
mobilized products. But still, the frequency of colonies per 1000 CD34+ cells was 
comparable (Figure 2-5b). Consistent with previous reports, BFU-E prevailed in 
HSC-nat (89.2% (range, 81.1-90.9%)) whereas the percentage of BFU-E (46.7% 
(range, 35.5-54.3%)) was similar to the granulocyte-macrophage compartment 
(52.7% (range, 44-64.5%)) in G-CSF HSC (Figure 2-5b). This strongly suggests that 
the precursor cells mobilized by natalizumab are different from those mobilized by 
G-CSF.  
 
DISCUSSION   
This is the first study investigating the bone marrow of patients receiving 
natalizumab for high-risk multiple sclerosis (MS). Our findings suggest that 
continued administration of the VLA-4 blocking antibody natalizumab stimulates 
hematopoiesis with ongoing increased numbers of CD34+ HSC in the BM and (as 
previously shown) potential mobilisation of clonogenic HSC into the peripheral 
blood22,23.  
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Figure 2-3: Phenotype and migratory capacity of CD34+ cells mobilized by G-CSF or CD49d 
blockade a) CD133 and CD184 (CXCR-4) expression of purified CD34+ cells from an apheresis 
of a healthy donor after G-CSF treatment (G-CSF CD34+ Cells) and a MS patient on 
natalizumab therapy (CD34+ Cells-nat). b) Median expression and ranges of the respective 
surface markers on G-CSF mobilized CD34+ cells compared to CD34+ cells-nat (n=3). c) 
CD34+ selected cells from leukaphereses derived from patients on natalizumab showed a 
significantly higher migration capacity in a transwell assay compared to G-CSF CD34+ cells. 
(n=3, *p < 0.05) 
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Figure 2-4: Gene expression profile of CD34+ cells mobilized by CD49d blockade Relative 
expression of p21, G0S2 and MMP9 in CD34+ selected HSC mobilized by natalizumab 
(HSC-nat) (n=3, *p < 0.05). Expression levels were normalized to mRNA levels in G-CSF 
mobilized CD34+ selected HSC. Dashed line= mRNA level of CD34+ cells mobilized by G-CSF 
set as 1. 
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Figure 2-5: Proliferation and clonogenicity (a) The graph depicts the cell numbers measured 
during cytokine-driven in-vitro expansion of G-CSF HSC and HSC-nat. (b) Clonogenicity 
quantified by the number of colonies per 1000 CD34+ cells detectable after 14 days in semi-solid 
medium (G-CSF HSC, n=10) and from MS patients after natalizumab therapy (HSC-nat, n=3).  
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The argument that many patients with MS might have elevated levels of circulating 
CD34+ cells due to the chronic inflammatory condition is invalidated by the 
negligible  CD34+ counts in MS patients not treated with natalizumab, who served 
as a control in our series53. At present we would not wish to exclude the possibility 
that the downregulation of adhesion molecules on CD34+ cells, as confirmed in the 
phenotypic analysis, makes more CD34+ cells occur in the aspirate simply because 
the HSCs are less adhesive and physically easier to dislocate. The high absolute 
levels of CD34+ cells in the BM aspirates argues nevertheless that natalizumab 
induces a compensatory increase in hematopoietic activity. Histological analysis of 
BM biopsies do not suggest a significant increase in overall BM cellularity (n=2, 
data not shown).  
 
The initial homing of HSC into bone marrow depends on the SDF-1/CXCR4 
chemokine axis54, where after the interaction between HSC and stromal cells via the 
various integrins keeps HSCs in the BM stem cell niche30. In theory, both pathways 
contribute to HSC mobilization in parallel. Therefore, by disrupting HSC retention, 
both G-CSF and natalizumab promote egress of HSC into the peripheral blood. Our 
present results show that natalizumab mobilizes HSC with a higher CXCR4 
expression but less expression of adhesion molecules (L-selectin, Pecam-1, LFA-1 
and CD44) when compared to CD34+ cells mobilized by G-CSF. This is in line with 
recent data suggesting that CXCR4 expression on HSC and SDF1 levels in BM are 
reduced after G-CSF administration55.  
 
The differences in surface molecule expression also reflect the alternative 
mechanisms involved in HSC mobilization. Since the SDF-1/CXCR4 axis plays a 
separate  essential role in HSC survival and repopulation in vivo56-58 and 
natalizumab induces HSC mobilization without interacting with SDF1 signalling59, 
CD49d blockade could be effective when used in combination with G-CSF.  
 
The lower expression of MMP-9 in CD34+ cells derived from apheresis products 
mobilized by natalizumab fits the induction of MMP-9 and the subsequent cleavage 
and reduction of SDF-1 described after G-CSF administration. Consistent with the 
upregulation of CXCR4, HSC mobilized by natalizumab were better at migration in 
a chemokine-driven transwell assay, which would predict better primary engraftment 
in vivo. This contrasts with a recent report of poor migration of CFU-C in the PB of 
patients receiving natalizumab. The reported difference may be because we 
investigated CD34+ selected cells derived from leukapheresis samples whereas 
Bonig et al22analyzed unmanipulated peripheral blood.  
 
The downregulation of prominin-1/CD133, a ubiquitous marker of both neural and 
hematopoietic stem/progenitor cells, argues  that natalizumab mobilizes a 
compartment that is beyond multipotential commitment, allowing that CD133+ 
expression has been linked with long-term repopulating potential in vivo60,61. The 
predominance of erythroid progenitors in the leukapheresis samples that we 
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mobilized with natalizumab is in line with our own evidence that the CD34+CD133- 
fraction contains a significantly higher proportion of erythroid BFU-E, whereas most 
of the leukocyte CFU-GM are concentrated in the CD34+CD133+ cells62. A 
predominance of erythroid progenitors after VLA-4 blockade20 in mice has been 
described in the literature .  
 
We could not observe a difference in the percentage of CD34+/CD38- cells between 
natalizumab and G-CSF mobilized samples. Since this phenotype has been 
associated with stemness and repopulation potential in several reports63,64, this  
finding suggests that the original repopulating HSC pool is still preserved after 
natalizumab mobilization of blood stem cells. 
 
Although cell cycle analysis revealed no difference in cell-cycle status between 
CD34+ cells after G-CSF and natalizumab, the higher expression of p21 suggests 
that disrupting the CD49d–stroma/matrix interaction might induce a compensatory 
decrease in cell cycle activity. This conjecture is supported by the lower expression 
of a gene involved in cell cycle progression, G0/S2.  
 
In summary, disrupting the integrin-based interaction between HSC and their niche 
may provide a complementary strategy for their mobilization. Although the long 
half-life of natalizumab presently precludes its use in patients scheduled for 
autologous transplantation or healthy donors, selective antagonists of CD49d could 
be developed. Our data suggest that CD49d blockade does not affect the 
SDF-1/CXCR-4 axis and could therefore improve conventional mobilization. 
Further in-vivo studies and clinical trials to evaluate the repopulating capacity of 
HSC mobilized by combined administration of G-CSF and CD49d antagonists are 
recommended.  
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Bornhauser1, Gerhard Ehninger1, Denis Corbeil2 and Rainer Ordemann1 
1Medical Clinic and Policlinic I, University Hospital, Dresden, Germany 
2Biotechnology Center, Technical University, Dresden, Germany 
 
RESULTS 
Identification of hematopoietic stem cell localization. To localize HSCs cocultured 
with MSCs, we have performed scanning electron microscopy. Interestingly, two 
distinct fractions of cells were observed (Figure 3-1A, B). HSCs were located either 
on the surface of the MSC layer (Figure 3-1A, black asterisks) or beneath (Figure 
3-1A, arrow). HSCs migrating underneath of MSCs were also detected (Figure 3-1A, 
B, outlined white asterisks). The time-lapse video microscopy analysis depicted the 
movement of an individual HSC migrating either above (Figure 3-1C, black arrow) or 
beneath (Figure 3-1C, white arrow) the MSC layer. By phase contrast microscopy, the 
HSC population underneath the MSC layer appeared as phase-dim cells whereas those 
located above as phase-bright cells (Figure 3-1D). The hematopoietic origin of these 
two cell fractions was confirmed by immunolabelling for CD45 (Figure 3-1E). Indeed, 
three optical confocal x-y–sections showed that both phase-bright and phase-dim cells 
were positive (Figure 3-1F, H, respectively) in contrast to MSCs (Figure 3-1G). Upon 
gently washings (for technical details see Design and Methods), the only remaining 
cells as those underneath MSC layer, i.e phase-dim cells (Figure 3-1I, J).  
 
Mesenchymal stromal cells surface is the dominant place for hematopoietic stem cells 
proliferation. To determine the influence of cellular localization on HSC expansion, 
we counted cells in their separated environments. Until day 5 of coculture, the cell 
number of the non-adherent and the phase-bright cells increased similarly and much 
faster than phase-dim cells (Figure 3-2A). After day 5 the number of non-adherent 
cells increased further, the number of phase-bright cells and phase-dim cells however 
remained constant (Figure 3-2A). Interestingly though non-adherent cells showed 
highest cell counts these cells were not in the G2/M phase shown by the propidium 
iodide (PI) staining. As shown in (Figure 3-2 B, C), the phase-bright cells (PB) 
contain a higher proportion in G2/M phase compared to non-adherent cells (NA) and 
phase-dim cells (PD) throughout the whole week of coculture, e.g. on day 3: PB 11.9 
± 2.7% vs NA 0 ± 0% (p < 0.001) and PD 3.6 ± 2.4% (p < 0.001) and on day 7: PB 
13.9 ± 1.0% vs NA 1.3 ± 1.2% (p < 0.001) and PD 2.7 ± 2.0% (p < 0.001). This is 
consistent with the expression of p21 which is an essential regulator for the 
quiescence of HSCs 65. P21 expression was significantly diminished in phase-bright  
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Figure 3-1. Distinct compartmentalization of HSCs cultured on MSCs. (A, B) Scanning electron 
microscopy analysis reveals that HSCs are either over the MSC layer (black asterisks) or beneath 
(white arrow). HSCs migrating underneath the MSC layer were also observed (outlined white 
asterisks). (C) Individual frames taken from time-lapse video depict of an individual HSC 
moving above (black arrow) and below (white arrow) the MSC layer for a period of 54 min. M 
indicates MSCs. (D) Phase-contrast microscopy analysis shows that HSCs located either above 
or beneath the MSC layer appeared as phase-bright and -dim cells, respectively. (E) Confocal 
laser scanning microscopy upon immunolabeling for CD45. (F) phase-bright cells on the surface 
of MSC layer. (G) MSC layer. (H phase-dim cells beneath MSC layer. (I) After removing 
phase-bright cells MSC layer with the cells beneath the layer (phase-dim cells) performing phase 
contrast microscopy. (J) A cross-section is shown using immunofluorescence imaging (actin, 
green; nucleus, blue; CD45, red). Scale bar: 20 µm. 
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Figure 3-2. Cell proliferation and cell cycle status. (A) Proliferation kinetics of the three cell 
fractions (N = 4). (B) Representative PI staining of cells from three distinct compartments at day 
3 and 7. (C) Dynamics of the three cell fractions in G2/M phase during one week coculture (N = 
3). (D) Relative expression of p21 in the three compartments at day 5 (N = 3, *p < 0.05). The 
data were normalized to the p21 expression in phase-bright cells, which was as arbitrarily set to 
1. 
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cells at day 5 (Figure 3-2D). These data indicate that in vitro MSC surface is enriched 
for proliferating progeny and phase-bright cells may detach from the MSC surface on 
reaching a non-adherent status.  
 
Hematopoietic stem and progenitor cells beneath the mesenchymal stromal cells layer 
remain immature. To investigate the impact of the localization on HSC differentiation, 
HSC phenotypes were measured by FACS analysis. CD34 is a classical HSC marker 
66, and CD34+CD38- cells are usually considered as a more primitive HSC population 
67. After apheresis we performed MACS purification of CD34+ cells. We could show 
in particular that both CD34+ and CD34+CD38- cells are enriched in the phase-dim 
fraction in comparison to the phase-bright cells and the non-adherent cells (Figure 
3-3). At day 2, almost 100% of phase-dim cells were CD34+CD38-, while the 
percentage of CD34+CD38- cells within the non-adherent and phase-bright fraction 
was below 75%. In the following days, CD34+ and CD34+CD38- cells in the 
phase-dim fraction decreased as well, but the drop was significantly delayed in 
comparison to the other cell fractions. Shown within the circles in Figure 3-3A, CD38 
was highly expressed in non-adherent cells and phase-bright cells compared to 
phase-dim cells at day 4. In addition, we were able to show a higher concentration of 
clonogenic CFU-C within phase-dim cells compared to non-adherent cells and 
phase-bright cells (PD 150 ± 20 colonies vs NA 119 ± 11 colonies (N = 6, p = 0.07) 
and PB 125 ± 20 colonies (N = 6, p < 0.05)).  
 
Cell divisions in distinct localizations. To determine the impact of localization on cell 
division, HSC generations were tracked by CFSE staining. Generation 0 was 
represented by the control, which was treated with Mitomycin. Two representative 
experiments are shown in (Figure 3-4A). At day 2, approximately 50% of phase-dim 
cells had not divided (generation 0), while generation 0 cells of the other two cell 
fractions were less than 20%. In the following days, phase-dim cells exhibited a 
higher proportion of cells having undergone less divisions compared to the other two 
cell fractions. Comparing the distribution of cell generations in the three 
compartments at day 2, 3 and 4, the data indicate the down regulating impact of the 
compartment beneath the MSC on cell division (Figure 3-4B). 
 
Immunophenotypes after each cell division. In order to determine the retention of the 
progenitor phenotype after each cell division, CFSE and CD34 double staining was 
performed in the three separated groups. After the first two cell divisions (in HSC 
generation 0, 1 and 2), almost all cells in all three localizations were CD34 positive 
(Figure 3-4C). However in generation 3 and 4 only the phase-dim population retained 
high percentage of CD34 expressing cells, which indicates their delayed 
differentiation compared to the other two cell fractions. In the following cell divisions, 
as shown in (Figure 3-4D), there were always more phase-dim cells that retained 
CD34 expression compared to the same HSC generation of the other two cell fractions. 
Taken together, the outcome of HSC division differed according to their localizations, 
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Figure 3. Immunophenotype of the HSCs in distinct compartments. (A) Representative FACS 
analysis of the three cell fractions from day 2 to 7. CD38+ cell fraction at day 4 was marked 
within circle. (B) CD34+CD38- proportion of the three cell fractions during one week coculture 
(N = 7). 
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Figure 4. Tracking cell division in distinct compartments using CFSE staining. (A) 
Representative FACS analysis of CFSE staining at day 2 and 3. Cell generations were identified 
according to the control cells which were treated with Mitomycin at day 0 (gray peak). (B) 
Distributions of cell generations of the three cell fractions at day 2, 3 and 4 (N = 3). Then the 
pattern of CD34 expression in different cell generations was studied. (C) Representative FACS 
analysis of CD34 and CFSE double staining at day 3 and 5. The dots in gray region are positive 
for CD34, the dots in white region are negative for CD34. Cell generations were identified 
according to the control cells which were treated with Mitomycin at day 0. (D) CD34+ 
expression over eight cell generations within the three cell fractions (N = 8). 
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suggesting that the more slowly proliferating HSCs grown beneath MSCs retain their 
stem cell characteristics during cell division. 
 
Immature hematopoietic stem cells migrate beneath the mesenchymal stromal cell 
layer. Next we ask whether more immature cells prefer the compartment beneath the 
MSC layer, migrating directly to this area in vitro. As already mentioned we detected 
phase-dim cells in newly established cocultures only after day 2. However when 
purified HSCs were cultured without MSCs in a cytokine supplemented medium for 
four days and then seeded on a MSC layer in a second culture as described in the 
method part we could see up to 6% phase-dim cells already after 5 hrs of coculture, 
indicating an increased capacity for migration beneath the MSC layer for primed 
HSCs. As shown in (Figure 3-5A) HSCs with 54.67% ± 2.55% CD34+CD38- 
expressing phenotype were plated on the MSC layer. After 5 hours those 
CD34+CD38- cells (78.23% ± 7.65%) were enriched in the phase-dim fraction, 
suggesting that more immature HSCs preferentially home beneath the MSC layer. 
 
CXCR4 and Integrins influence phase-dim cell formation. Recently we demonstrated 
that CXCR4 is upregulated in the adherent-cell fraction in comparison to the 
non-adherent cell fraction 43. Other adhesion molecules such as integrins is also 
important for homing and migration 48,68,69. The assay described above allowed us to 
investigate the impact of the surface molecules on the primary attachment and 
migration of HSC underneath the MSC layer. First we blocked integrin ß1 as 
described in the methods section. As shown in Figure 5B phase-bright cells were 
reduced from 69.89% ± 4.08% to 40.56% ± 12.45% (p < 0.01). Phase-dim cells were 
reduced from 7.18% ± 1.50% to 3.38% ± 1.19% (p < 0.01) indicating that at least 
integrin ß1 takes part in the process of HSCs adhesion on the MSC surface and 
migration beneath the MSC layer. Next we blocked CXCR4 by adding AMD3100 
(Figure 3-5B). Although the count of phase-bright cells was not reduced (69.89% ± 
4.08% vs 75.33% ± 8.42%), phase-dim cells were diminished from 7.18% ± 1.50% to 
3.19% ± 0.77% (p < 0.01), indicating that in our assay CXCR4 plays a role in HSC 
migration beneath the MSC layer. Finally by blocking both CXCR4 and Integrin ß1, 
the count of phase-dim cells was further reduced to 1.97% ± 0.18% in comparison to 
individual blocking of integrin ß1 or CXCR4 (3.38% ± 1.19% and 3.19% ± 0.77%) 
indicating that both integrins and CXCR4 are involved in the migration of HSCs 
beneath the MSC feeder layer. Our data confirms also that CXCR4 has no impact on 
the adhesiveness as already shown in our paper published recently 43. Blocking 
P-selectin as control showed not significant decrease of phase-bright and phase-dim 
cells.  
 
DISCUSSION 
Many studies have demonstrated that HSCs can be expanded in cytokine-driven 
culture. However, this kind of expansion is accompanied by concomitant 
differentiation and gradual loss of stemness. In recent years, it has been shown that 
stromal feeder layers can be used to support HSC expansion. It has become evident  
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Figure 3-5. (A) Enrichment of CD34+CD38- cells in phase-dim fraction. Cells containing around 
50% CD34+CD38- cells were plated on MSC layer. After 5 hours CD34+CD38- proportion in 
phase-dim cells was enriched up to 80% (N = 4, *p < 0.01). (B) Blocking experiments for 
P-selectin, Integrin ß1 and CXCR4. By blocking Integrin ß1 or CXCR4 or both, percentages of 
cell numbers of phase-bright or phase-dim cells were down-regulated (N = 4, *p < 0.01 (relative 
to control); #p < 0.05 (relative to individual blocking for Integrin ß1 or CXCR4)).  
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that the interaction between HSCs and MSCs is an important issue for keeping HSCs 
quiescent both in vivo and in vitro 30. We and others have shown that cell-to-cell 
contact in vitro has a significant impact on HSCs in terms of functional, phenotypic, 
and clonogenic parameters. We have also demonstrated that direct contact with MSCs 
affects the migratory behavior and gene expression profile of CD133+ HSCs during 
ex vivo expansion 43. In the present report, the distribution of HSCs in the coculture 
assay has been investigated in more detail. We have observed that three different 
localizations in coculture system represent distinct microenvironments for HSCs 
having a significant impact on their fate in vitro. By performing phase-contrast, 
confocal and electron microscopy, we separated HSCs which were non-adherent, cells 
adherent to the surface of the MSC layer, and cells which had migrated beneath the 
feeder layer. A confluent MSC layer may serve as a boundary between two distinct 
compartments. These spatial constraints influence the proliferation and differentiation 
of HSCs.  
 
One remarkable difference is the cell cycle status of cultured HSC. It is known that 
immediately after HSCs are isolated from peripheral blood (PB), they usually are in 
G0/G1 70. Their status however changes if the cells are plated out in expansion assays 
with stimulating factors32. In our study phase-bright cells significantly and 
consistently showed an increase of G2/M cells (over 10%) throughout the whole 
culture period. In contrast among the non-adherent cells and the phase-dim cells the 
G2/M phase was almost completely lacking. Interestingly, G2/M phases happen 
mainly on the surface and not in a non-adherent status. On the other hand, the number 
of non-adherent cells increased continuously, suggesting that the adherent fraction 
supplies the non-adherent fraction with detaching cells. We have evidence that the 
cell-to-cell contact on the surface of the MSC layer promotes the cell cycle, however 
the mechanism has still not been clarified in detail. 
 
Interestingly we found that in our coculture system the translocation between HSCs 
on the surface and those beneath the MSC layer was between two distinct 
compartments. Performing serial studies we found that phase-dim cells retained a 
more immature phenotype in comparison to the HSCs on the surface of the MSC layer 
and had a significantly delayed rate of cell division in comparison to the other two cell 
fractions. Therefore we speculate that the MSC boundary layer has a significant effect 
on HSC fate. Admittedly, HSCs are highly motile and able to move between the 
compartments. Our daily measurements still represent snap-shots taken at defined 
time-points, which may not represent the whole complex dynamics of the process.  
 
It is still not clear whether the environment beneath the MSC layer actively keeps 
HSCs in an immature state or creates a ‘niche’ atmosphere which specifically attracts 
HSCs. We speculate that both mechanisms are involved. We could at least 
demonstrate that CD34+CD38- HSCs prefentially migrate through the MSC layer.  
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Figure 3-6. Graphic of the HSC/MSC coculture system in vitro. (A) Migration towards and 
retention of HSCs to MSCs is mediated by SDF1/CXCR4 and adhesion molecules such as 
Integrins. (B) The MSC layer serves in vitro as a boundary of two distinct compartments, i.e. the 
MSC surface mediating cell proliferation and a niche-like compartment beneath the layer. Here 
beneath the layer cells (PD) show a delayed cell-cycle activity and a more immature phenotype. 
In opposite HSCs on the MSC surface (PB) revealed significantly more proliferation activity. We 
assume that cells from the MSC surface are released into the supernatant, the third 
microenvironment (NA) in the coculture system. The graphic demonstrates a dynamic interplay 
of HSCs within the three compartments. 
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In addition, the interaction between HSCs and MSCs via soluble factors 
(SDF1/CXCR4) or adhesion molecules (integrins) has an impact on HSC migration 
between the two microenvironments. Phase-dim cell formation could be reduced by 
blocking integrins and CXCR4. This effect could be enhanced even further by 
combined blockade, indicating that ß1-integrins and the SDF1/CXCR4 axis play 
synergistic roles in phase-dim cell formation. Interestingly the count of phase-bright 
cells was not reduced by AMD3100, indicating that CXCR4 is not relevant in 
adhesiveness confirming our recently published data 43. 
 
In summary, we can distinguish three different compartments in our coculture system; 
i) supernatant, i.e. the milieu where HSCs are growing without direct contact with 
MSCs; ii) surface of MSCs and iii) the environment beneath the MSC layer. All three 
locations are dynamically linked with each other, and are characterized by special 
features. Specifically, the niche-like microenvironment (i.e. beneath MSCs) probably 
recruits and retains HSCs with more primitive properties whereas the other favors the 
active expansion of HSC (MSC surface).  
 
Interestingly, in vivo there is a similar but certainly even more complex system of 
niches. It has been reported that quiescent HSCs are preferentially located in 
osteoblastic niches, while more actively cycling and self-renewing HSCs are kept in 
the perivascular niche 30,71. The three-compartment coculture system probably mimics 
the cooperation of stem cell niches in vivo. 
 
The model of the HSC “in vitro niche” is demonstrated in (Figure 3-6), showing the 
MSC surface as the major site of HSC proliferation and the microenvironment 
beneath the MSC layer as the storage site of more primitive cells, all affected by an 
orchestra of various soluble and non-soluble signals. Further investigations are needed 
to study the complex mechanism of hematopoietic stem cell expansion in vitro, 
including investigation of the repopulating potential of the different cell fractions by 
performing in-vivo repopulation experiments. 
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ABBREVIATIONS  
z ALL: Acute lymphoblastic leukemia 
z AML: Acute myeloid leukemia 
z BFU-E: Burst-forming unit-erythroid 
z BM: Bone marrow 
z CFU-C: Colony-forming units in culture 
z CFU-GEMM: Colony-forming unit - granulocyte, erythroid, macrophage, 
megakaryocyte 
z CFU-GM: Colony forming unit-granulocyte and macrophage 
z CFU-M: Colony forming unit-macrophage 
z CLL: Chronic lymphocytic leukemia 
z CML: Chronic myeloid leukemia 
z CXCR4: CXC chemokine receptor 4 
z DMSO: Dimethyl sulfoxide 
z FACS: Fluorescence activated cell sorting 
z FCS: Fetal cow serum 
z FLT3-L: Fetal liver tyrosine kinase-3 ligand 
z GAPDH: Glyceraldehyde-3-phosphate dehydrogenase 
z h: hours 
z HSA: Human serum albumin 
z HSC: Hematopoietic stem cells 
z ICAM-1: Intercellular adhesion molecule-1 
z IL-3: Interleukin-3 
z LTC-IC: Human long-term culture-initiating cell 
z MACS: Magnetic activated cell sorting  
z MSC: Mesenchymal stromal cells 
z P21: Cyclin-dependent kinase inhibitor 1A 
z PB: Peripheral blood 
z PBS: Phosphate buffered saline 
z RT-PCR: Real-time reverse transcription-polymerase chain reaction 
z SCF: Stem cell factor 
z SDF-1: Stromal cell–derived factor–1 
z TNC: Total nucleated cells 
z TPO: Thrombopoietin  
z UCB: Umbilical cord blood  
z VCAM-1: Vascular cell adhesion molecule-1 
z VEGF: Vascular endothelial growth factor 
z VLA: Very late antigen 
 
 43
THESES 
Hematopoietic stem cells (HSCs) are defined by their ability to give rise to all types of 
blood cells. Hematopoietic stem cell transplantation (HSCT) has become a well 
established treatment modality for hematological malignancies and non-malignant 
disorders.  
 
Part 1: HSC isolation from extra-embryonic tissue. 
1. Fetal stem cells in Umbilical cord blood (UCB) are speculated to be more 
primitive in comparison to adult stem cells. Hereby, UCB was introduced as an 
attractive HSC source for HSCT. In order to increase amount of fetal HSCs, 
recently extra-embryonic tissue was used as a complemental source to UCB. 
2. The axis of the chemokine receptor CXCR4 and its ligand SDF-1 is important for 
trafficking and homing of HSC. Bicyclam AMD3100, a CXCR4 antagonist, in 
combination with G-CSF is able to induce a significant mobilization of CD34+ 
cells.  
3. Human placenta is a potent hematopoietic niche containing hematopoietic stem 
and progenitor cells throughout development We can demonstrate that the 
CXCR4 antagonist AMD3100 mobilise placenta derived CD34+ cells ex utero 
already after 30 min of incubation and may further enhance the efficacy of 
harvesting placenta-derived HSC. 
 
Part 2: CD49d blockade to mobilize a subset of HSCs. 
1. In clinic, HSCs of adult healthy donor were mobilized out of bone marrow into 
the peripheral blood (PB) after G-CSF treatment. The HSCs were then collected 
and used in HSCT.  
2. The alpha4 integrin CD49d is involved in migration and homing of hematopoietic 
stem cells (HSC). Therapeutic application of natalizumab, an anti-CD49d 
antibody, in patients with multiple sclerosis (MS) has been associated with 
increased levels of circulating CD34+ progenitors. 
3. We compared circulating HSCs from MS patients after natalizumab treatment and 
HSCs mobilized by G-CSF in healthy volunteers, with regard to their migratory 
potential, clonogenicity and gene expression. Our data indicate that G-CSF and 
CD49d blockade mobilize different HSC subsets and suggest that both strategies 
may be differentially applied in specific cell therapy approaches. 
 
Part 3: Modelling the Niche Compartments in-vitro. 
1. In order to further improve the clinical outcome of HSC transplantation, many 
groups are focusing on ex vivo maintain or expand HSC. 
2. HSCs located in the bone marrow are interacting with a specific 
microenvironment referred to as the stem cell niche, which regulates their fate in 
terms of quiescence, self-renewal and differentiation. An orchestra of signals 
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mediated by soluble factors and/or cell-to-cell contact keeps the balance and 
homeostasis of self-renewal, proliferation and differentiation in vivo.  
3. To investigate the communication between HSCs and the niche, coculture assays 
with mesenchymal stromal cells (MSCs) were performed in vitro.  
4. Cell-to-cell contact has a significant impact on hematopoietic stem cells 
expansion, migratory potential and stemness. The spatial relationship between 
hematopoietic stem cells and mesenchymal stromal cells is critical for HSC 
maintenance during ex-vivo expansion. 
5. We defined three distinct localizations of HSCs relative to MSC layer: (i) those in 
supernatant (non-adherent cells); (ii) cells adhering on the surface of 
mesenchymal stromal cells (phase-bright cells) and (iii) cells beneath the 
mesenchymal stromal cells (phase-dim cells). 
6. Our data suggest that the mesenchymal stromal cell surface is the dominant 
location where hematopoietic stem cells proliferate, whereas the compartment 
beneath the mesenchymal stromal cell layer seems to be mimicking the stem cell 
niche for more immature cells. Our data provide novel insight into the 
construction and function of three-dimensional HSC–MSC microenvironments. 
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